Maroie Barkati

Dr. Maroie Barkati

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DGDavid K. Gaffney
David K. Gaffney
BKBronwyn King
Bronwyn King
AVAkila N. Viswanathan
Akila N. Viswanathan
MBMaroie Barkati
Maroie Barkati
SBSushil Beriwal
Sushil Beriwal
WBWalter Bosch
Walter Bosch

1 August 2021 in Gynecologic Oncology
Verified
Journal Article
Closed access
MBMelica Nourmoussavi Brodeur
Melica Nourmoussavi Brodeur
RDRomain Dejean
Romain Dejean
MBMarie-Claude Beauchemin
Marie-Claude Beauchemin
VSVanessa Samouëlian
Vanessa Samouëlian
BCBéatrice Cormier
Béatrice Cormier
MBMaroie Barkati
Maroie Barkati

9 September 2022 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
DGDavid Grajales
David Grajales
FPFabien Picot
Fabien Picot
RSRoozbeh Shams
Roozbeh Shams
FDFrédérick Dallaire
Frédérick Dallaire
GSGuillaume Sheehy
Guillaume Sheehy
SKSamuel Kadoury
Samuel Kadoury
Transperineal biopsy and high-dose-rate (HDR) brachytherapy are two needle-based procedures for diagnosing and treating prostate cancer (PCa), respectively. HDR brachytherapy allows the delivery of a considerable dose of radiation to the tumor site using temporary implants while reducing the surrounding tissue involvement.1,2 Although using transrectal ultrasound (TRUS)-guided biopsy is the standard of care, it can have up to 30% false-negative rates and does not allow in situ characterization.3,4 It is clear that the efficiency of both techniques relies significantly on accurate localization of the tumor and needle.

10 March 2017 in Andrology
Verified
Journal Article
Open access
PDF file
DTDaniel Taussky
Daniel Taussky
MBMaroie Barkati
Maroie Barkati
SCS. Campeau
S. Campeau
KZK. Zerouali
K. Zerouali
ANA. Nadiri
A. Nadiri
GDG. Delouya
G. Delouya
Summary: There is increasing interest in periprostatic fat and its influence on prostate cancer aggressiveness. In vitro data suggest that adipose stromal/stem cells (ASCs) can increase production of cytokines and growth factors resulting in invasive growth and metastasis in prostate cancer. The objective of the study was to determine the interaction between 5α‐reductase inhibitors (5ARIs) and periprostatic adipose tissue (PPAT) and factors of prostate cancer aggressiveness. In this retrospective study, we identified 61 patients treated with 5ARIs for a period of ≥12 months before undergoing radiation therapy (brachytherapy or external beam radiotherapy). The control group consisted of 117 patients without any exposure to 5ARIs. Prior to being treated, all patients underwent abdominal computed tomography (CT). To measure PPAT, we defined the fat pad anteriorly to the prostate, as well as the intra‐abdominal visceral adipose tissue (VAT) and subcutaneous tissue (SAT) at the level of L4/L5. All contours were performed manually. These adipose tissue measurements were correlated with the Cancer of the Prostate Risk Assessment (CAPRA) score using Pearson correlation coefficient. Differences in fat contents were evaluated using Student's t‐test. Median time on 5ARIs for the 61 patients was 12 months (range 12–96). Patient on 5ARIs had a significantly (p < 0.001) smaller PPAT (0.4, SD 0.5) than patients without a 5ARI (0.6 cc, SD 0.4). There was no significant correlation between the CAPRA score and fat measurements when adjusted for 5ARI use (p = 0.18). In non‐5ARI users, BMI was not correlated with PPAT but was correlated with SAT and VAT volume and its density. There were no significant differences in diabetics (p = 0.3), metformin users (p = 0.4) or statin users (p = 0.09) between both groups. 5ARIs taken for at least 12 months induce changes in PPAT volume. Whether these changes or the extent of changes will have an influence on outcome remains unknown.

1 November 2021 in Brachytherapy
Verified
Journal Article
Closed access
TRThomas Reynaud
Thomas Reynaud
LHLara Hathout
Lara Hathout
DCDamien Carignan
Damien Carignan
MBMaroie Barkati
Maroie Barkati
AMAndre-Guy Martin
Andre-Guy Martin
EVEric Vigneault
Eric Vigneault

1 January 2016 in Journal of Contemporary Brachytherapy
Verified
Journal Article
Open access
OLOlivier Lauche
Olivier Lauche
GDGuila Delouya
Guila Delouya
DTDaniel Taussky
Daniel Taussky
CMCynthia Menard
Cynthia Menard
DBDominic Béliveau-Nadeau
Dominic Béliveau-Nadeau
MBMaroie Barkati
Maroie Barkati
Purpose : To validate the feasibility of a single-fraction high-dose-rate brachytherapy (HDRBT) boost for prostate cancer using real-time transrectal ultrasound (TRUS) based planning. Material and methods : From August 2012 to September 2015, 126 patients underwent a single-fraction HDRBT...